Tadeus John Wieczorek, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastritis | 2 | 2016 | 199 | 0.310 |
Why?
|
| Gastric Mucosa | 2 | 2016 | 602 | 0.280 |
Why?
|
| Helicobacter Infections | 2 | 2016 | 390 | 0.270 |
Why?
|
| Cardia | 1 | 2003 | 61 | 0.220 |
Why?
|
| Granular Cell Tumor | 1 | 2001 | 48 | 0.190 |
Why?
|
| Carcinoma | 3 | 2019 | 2332 | 0.160 |
Why?
|
| Helicobacter pylori | 2 | 2016 | 380 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2022 | 480 | 0.150 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2018 | 59 | 0.140 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 426 | 0.140 |
Why?
|
| Nipples | 1 | 2018 | 227 | 0.130 |
Why?
|
| Fibroma | 1 | 2017 | 197 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2003 | 836 | 0.130 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 21207 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2000 | 811 | 0.110 |
Why?
|
| Epithelial Cells | 2 | 2003 | 3703 | 0.110 |
Why?
|
| Thyroid Neoplasms | 2 | 2018 | 2360 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2001 | 957 | 0.110 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2016 | 326 | 0.100 |
Why?
|
| Electromagnetic Fields | 1 | 1994 | 289 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 793 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2016 | 2885 | 0.100 |
Why?
|
| Magnetics | 1 | 1994 | 597 | 0.090 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 13013 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 1099 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2002 | 2334 | 0.090 |
Why?
|
| Chromatin | 1 | 2001 | 2981 | 0.080 |
Why?
|
| Thyroid Gland | 1 | 2016 | 1171 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2003 | 6395 | 0.080 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 767 | 0.080 |
Why?
|
| Splenic Neoplasms | 1 | 2008 | 97 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5804 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 4363 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2001 | 1623 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 11095 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1994 | 3782 | 0.060 |
Why?
|
| Image Enhancement | 1 | 1994 | 2880 | 0.060 |
Why?
|
| Pubic Bone | 1 | 2003 | 31 | 0.050 |
Why?
|
| Hemangioma | 1 | 2008 | 727 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2002 | 12171 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 9419 | 0.050 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2002 | 161 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 419 | 0.050 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2000 | 31 | 0.050 |
Why?
|
| Breast | 2 | 2019 | 1976 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2001 | 287 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 355 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1703 | 0.040 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 250 | 0.040 |
Why?
|
| Aged | 12 | 2022 | 171502 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 570 | 0.040 |
Why?
|
| Biopsy | 2 | 2016 | 6792 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 905 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2001 | 725 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2019 | 243 | 0.040 |
Why?
|
| Middle Aged | 10 | 2022 | 223487 | 0.040 |
Why?
|
| Necrosis | 1 | 2001 | 1616 | 0.040 |
Why?
|
| Cadherins | 1 | 2022 | 905 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 1505 | 0.030 |
Why?
|
| Antigens | 1 | 2002 | 1443 | 0.030 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 59626 | 0.030 |
Why?
|
| Adult | 9 | 2022 | 223646 | 0.030 |
Why?
|
| Female | 14 | 2022 | 397187 | 0.030 |
Why?
|
| Mitosis | 1 | 2001 | 1178 | 0.030 |
Why?
|
| Keratins | 1 | 2017 | 499 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2001 | 1337 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2002 | 1247 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 687 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2004 | 1982 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14729 | 0.030 |
Why?
|
| Humans | 17 | 2022 | 768171 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 2000 | 4916 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 2048 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 15453 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1906 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 1157 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 552 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2016 | 913 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 2931 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4120 | 0.020 |
Why?
|
| Prognosis | 2 | 2018 | 30009 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 1281 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 4058 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 2541 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7213 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3620 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 3187 | 0.020 |
Why?
|
| Male | 7 | 2016 | 364731 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6316 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2019 | 6004 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 60066 | 0.020 |
Why?
|
| Artifacts | 1 | 1994 | 1926 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3670 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20762 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2004 | 287 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9374 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 1132 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 26421 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2018 | 54924 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1994 | 3573 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 630 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2004 | 411 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18415 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 81760 | 0.010 |
Why?
|
| Adolescent | 2 | 2017 | 89169 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 36741 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 671 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 11101 | 0.010 |
Why?
|
| Neutropenia | 1 | 2004 | 892 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7477 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 24318 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 1179 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 2934 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2003 | 1786 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2016 | 65379 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39354 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 40220 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 1514 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 6847 | 0.010 |
Why?
|
| Algorithms | 1 | 1994 | 14164 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 4913 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 41753 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 2463 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 8316 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10763 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 74944 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 17142 | 0.000 |
Why?
|